Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-02-22 | Mr. Cipriani became a Director of Aethlon Medical, Inc. in June 2018. ... Our Board of Directors presently has an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee, on each of which Drs. Fisher and Shah, Mr. Broenniman and Ms. Johnson serve as independent directors. Mr. Broenniman is Chairman of the Audit Committee, Dr. Shah is Chairman of the Compensation Committee and Mr. Broenniman is Chairman of the Nominating and Corporate Governance Committee. ... The following table provides membership and meeting information for fiscal year 2018 for each of the Board committees: ... Guy F. Cipriani (1) Audit Committee member. (1) Appointed February 19, 2019. |
| 2019-09-20 | Guy F. Cipriani, Director Mr. Cipriani became a Director in June 2018. ... Our Board of Directors presently has an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee, on each of which Drs. Fisher and Shah, Mr. Broenniman and Ms. Johnson serve as independent directors. Mr. Cipriani also serves on the Compensation Committee of the Board of Directors. Director Compensation for 2019 Fiscal Year Mr. Cipriani earned $25,500 related to his role as a director, and as a member of our Nominating and Corporate Governance Committee. Mr. Cipriani also received RSUs valued at $50,000 for joining our Board per the 2012 Directors Compensation Program. |
| 2020-07-28 | Guy F. Cipriani, Director, Age 50. Mr. Cipriani has served as a director of the Company since June 2018. He serves on the Compensation Committee. Director compensation for 2020 fiscal year: $69,000. |
| 2021-07-28 | In the fiscal year ended March 31, 2021, Mr. Cipriani earned $29,750 for his role as a director. Mr. Cipriani also received RSU’s valued at $35,000 for her ongoing service as a Board member pursuant to the Non-Employee Directors Compensation Program. |
| 2022-07-27 | Mr. Cipriani has served as a director of the Company since June 2018 and as our Senior Vice President, Chief Business Officer since January 2021. Prior to joining the Company, Mr. Cipriani was Chief Business Officer at Microbion Corporation, a company focused on the development of a new class of antibiotic therapies for difficult to treat and resistant infections, since July 2017. From July 2012 to July 2017, he served as Vice President of Business Development at Cascadian Therapeutics and prior to that role, Mr. Cipriani served as Vice President of Business Development at Cardiome Pharma Corp., or Cardiome. Prior to Cardiome, Mr. Cipriani served as Senior director of Business Development for TransForm Pharmaceuticals, Inc. Mr. Cipriani began his pharmaceutical industry career at Eli Lilly & Company as a member of their Corporate Business Development team where he completed multiple in-licensing and out-licensing transactions for commercial, clinical and preclinical state assets. Mr. Cipriani holds a B.S.E.E., High Honors from Rochester Institute of Technology and an MBA from the Kellogg Graduate School of Management at Northwestern University. We believe that Mr. Cipriani is qualified to serve as our director due to his vast experience in business and transactional development and execution in the life sciences industry. |
| 2023-07-27 | Guy F. Cipriani, Senior Vice President, Chief Business Officer and Director, age 53. No director compensation reported for fiscal year ended March 31, 2023. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22